These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21752948)

  • 1. Subcutaneous immunization with baculovirus surface-displayed hemagglutinin of pandemic H1N1 Influenza A virus induces protective immunity in mice.
    Prabakaran M; Meng T; He F; Yunrui T; Qiang J; Lin RT; Kwang J
    Clin Vaccine Immunol; 2011 Sep; 18(9):1582-5. PubMed ID: 21752948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection.
    Prabakaran M; Madhan S; Prabhu N; Qiang J; Kwang J
    J Virol; 2010 Apr; 84(7):3201-9. PubMed ID: 20071572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge.
    Prabakaran M; Kolpe AB; He F; Kwang J
    Vaccine; 2013 Feb; 31(10):1385-92. PubMed ID: 23328313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-protective efficacy of baculovirus displayed hemagglutinin against highly pathogenic influenza H7 subtypes.
    Prabakaran M; Kumar SR; Raj KV; Wu X; He F; Zhou J; Kwang J
    Antiviral Res; 2014 Sep; 109():149-59. PubMed ID: 24997413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles.
    Kim YC; Yoo DG; Compans RW; Kang SM; Prausnitz MR
    J Control Release; 2013 Dec; 172(2):579-88. PubMed ID: 23643528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination against influenza with recombinant hemagglutinin expressed by Schizochytrium sp. confers protective immunity.
    Bayne AC; Boltz D; Owen C; Betz Y; Maia G; Azadi P; Archer-Hartmann S; Zirkle R; Lippmeier JC
    PLoS One; 2013; 8(4):e61790. PubMed ID: 23626728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice.
    Prabakaran M; Madhan S; Prabhu N; Geng GY; New R; Kwang J
    Antiviral Res; 2010 May; 86(2):180-7. PubMed ID: 20153776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virus.
    Rajesh Kumar S; Syed Khader SM; Kiener TK; Szyporta M; Kwang J
    PLoS One; 2013; 8(6):e63856. PubMed ID: 23762234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chitosan as an adjuvant for parenteral inactivated influenza vaccines].
    Gendon IuZ; Markushin SG; Krivtsov GG; Akopova II
    Vopr Virusol; 2008; 53(5):14-9. PubMed ID: 19069787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.
    Falkeborn T; Bråve A; Larsson M; Akerlind B; Schröder U; Hinkula J
    PLoS One; 2013; 8(8):e70527. PubMed ID: 23950951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aerosol Delivery of a Candidate Universal Influenza Vaccine Reduces Viral Load in Pigs Challenged with Pandemic H1N1 Virus.
    Morgan SB; Hemmink JD; Porter E; Harley R; Shelton H; Aramouni M; Everett HE; Brookes SM; Bailey M; Townsend AM; Charleston B; Tchilian E
    J Immunol; 2016 Jun; 196(12):5014-23. PubMed ID: 27183611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of mice against pandemic H1N1 influenza virus challenge after immunization with baculovirus-expressed stabilizing peptide fusion hemagglutinin protein.
    Yang E; Cho Y; Choi JA; Choi Y; Park PG; Park E; Lee CH; Lee H; Kim J; Lee JM; Song M
    J Microbiol Biotechnol; 2015 Feb; 25(2):280-7. PubMed ID: 25394603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sublingual administration of bacteria-expressed influenza virus hemagglutinin 1 (HA1) induces protection against infection with 2009 pandemic H1N1 influenza virus.
    Shim BS; Choi JA; Song HH; Park SM; Cheon IS; Jang JE; Woo SJ; Cho CH; Song MS; Kim H; Song KJ; Lee JM; Kim SW; Song DS; Choi YK; Kim JO; Nguyen HH; Kim DW; Bahk YY; Yun CH; Song MK
    J Microbiol; 2013 Feb; 51(1):130-5. PubMed ID: 23456722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective efficacy of a human endogenous retrovirus envelope-coated, nonreplicable, baculovirus-based hemagglutin vaccine against pandemic influenza H1N1 2009.
    Choi JY; Gwon YD; Kim JK; Cho YD; Heo YK; Cho HS; Choi TJ; Poo HR; Oh YK; Kim YB
    PLoS One; 2013; 8(11):e80762. PubMed ID: 24260476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.